Drugmakers to hike prices on over 200 drugs
By Michael Erman and Carl O’Donnell
NEW YORK: Drugmakers including Pfizer Inc , GlaxoSmithKline PLC and Sanofi SA are planning to hike U.S. list prices on more than 200 drugs in the United States.
According to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.
Nearly all of the price hike will be below 10%, and around half of them are in the range of 4 to 6%, said 3 Axis co-founder Eric Pachman.
The median price hike is around 5%, he said.
More price hike are expected to be announced later this week, which could affect the median and range.
Many branded drugmakers have pledged to keep their U.S. list price hike below 10% a year, under pressure from politicians and patients.
Drugmakers often negotiate rebates on their list prices in exchange for favorable treatment from healthcare payers.
As a result, health insurers and patients rarely pay the full list price of a drug.
Pfizer price hike
Pfizer will hike prices on more than 50 drugs, including its cancer treatmentIbrance, which is on track to bring in nearly $5 billion in revenue this year, and rheumatoid arthritis drug Xeljanz.
Pfizer spokeswoman Amy Rose confirmed the company’s planned price increases.
She said the company plans to increase the list prices on around 27% of its portfolio in the United States by an average of 5.6%.
Of the medicines with increases, she said 43% of them are sterile injectibles, and many of those increases are less than $1 per product.
GlaxoSmithKline price hike
GlaxoSmithKline said it will raise prices on more than 30 drugs.
The company will raise prices on the blockbuster respiratory treatments it delivers through its Ellipta inhaler.
Its recently acquired cancer drug Zejula and on several products in its HIV-focused ViiV joint venture, according to 3 Axis Advisors. Price increases ranged between 1Sanifi
Also read: USFDA declines to approve GSK’s HIV inj.
Sanofi price hike
Sanofi said it will hile prices on around 10 of its drugs, with hikes ranging between 1% and 5%.
The drugmaker noted the increases are in line with its commitment to not raise prices above medical inflation.
Teva Pharmaceuticals price hike
Teva Pharmaceutical Industries Ltd raised prices on more than 15 drugs, in some cases by more than 6%, according to 3 Axis Advisors.
A Teva spokesperson said the company regularly reviews prices in the context of market conditions, availability and cost of production.
3 Axis advises pharmacy industry groups on identifying inefficiencies in the U.S. drug supply chain and has provided consulting work to hedge fund billionaire John Arnold, a prominent critic of high drug prices.